French vaccine developer Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles. The biopharma is shuttering its location in Nantes, a spot…
Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines. And it’s paying…
The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three months to buy time to review recently submitted information. Having…
A federal commission is warning that the U.S. is losing its innovative edge, arguing that the nation needs to “reimagine the federal science enterprise” by streamlining funding and incorporating artificial…
AbbVie is opening submissions for an award that will provide one Canadian biotech with free access to lab space and executive insights from the Big Pharma. The most recent iteration…
As the FDA’s Commissioner’s National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having secured ultrafast drug reviews, questions and criticisms about the initiative have been…
Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw…
A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study also hitting an enrollment target, triggering a $200 milestone payment due…
Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus the chance to net up to $400 million in biobucks. Last…
VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that has already reeled in a partnership with Biogen. The biopharma has paid…